Clinical Trials

Graft vs Host Disease, Neoplasms, Plasma Cell

NCT00339963 2026-05-01

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma

Completed

1,340 enrolled

Phase NA Active not recruiting

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Plasma Cell

NCT05889221 2026-04-30

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

74 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03633955 2026-04-23

REALIZE

Phase 1 Recruiting

60 enrolled

Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT07532473 2026-04-20

REMAKE

Not yet recruiting

300 enrolled

Phase 1/2 Active not recruiting

Neoplasms, Plasma Cell

NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

70 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06870760 2026-04-16

Pre-malignant States to Hematologic Malignancies in Firefighters

Recruiting

300 enrolled

Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Paraproteinemias, Neoplasms, Plasma Cell

NCT05336383 2026-04-15

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Phase 2 Recruiting

30 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07529782 2026-04-14

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

15 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

75 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Completed

50 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07519187 2026-04-09

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

20 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Recurrence, Neoplasms, Plasma Cell

NCT06986434 2026-04-08

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

20 enrolled

Lymphoma, Recurrence, Neoplasms, Plasma Cell

NCT00430365 2026-04-06

IFM2005-02

Phase 3 Completed

614 enrolled

Neoplasms, Plasma Cell

NCT01191060 2026-04-06

IFM/DFCI2009

Phase 3 Completed

700 enrolled

Disease Progression, Neoplasms, Plasma Cell

NCT05763563 2026-03-31

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Phase NA Completed

20 enrolled

Phase NA Not yet recruiting

Leukemia, Lymphoma, Neoplasms, Plasma Cell

NCT06971848 2026-03-30

ETCABIO

70 enrolled

GastrointestinalLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellThoracic

Immunoglobulin Light-chain Amyloidosis, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Carcinoma, Bronchogenic, Heart Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Follicular, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT04680468 2026-03-23

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

41 enrolled

Neoplasms, Plasma Cell

NCT07354555 2026-03-20

MMExFFPE

Not yet recruiting

15 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02952508 2026-03-18

CLOVER-WaM

120 enrolled

Phase 1 Active not recruiting

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

19 enrolled

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04328662 2026-03-04

A Study of Ninlaro in Real World Clinical Practice in China

Completed

482 enrolled

Phase 1 Not yet recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07297160 2026-03-04

CALySSEY

88 enrolled

GenitourinaryLymphoidOther hematologic neoplasmPlasma cellSarcoma

Kidney Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Phase 4 Not yet recruiting

80 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT05745285 2026-02-20

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Phase NA Recruiting

400 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT07410403 2026-02-13

AI

Enrolling by invitation

10 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

40 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04751877 2026-02-10

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

270 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

40 enrolled

Phase 3 Active not recruiting

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts

Phase EARLY_PHASE1 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01269593 2026-01-15

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

63 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT05063591 2026-01-15

BRUOG-407

Phase NA Completed

18 enrolled 8 charts

Leukemia, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT05625971 2026-01-07

NIRVANA

Completed

36 enrolled

Neoplasm, Residual, Neoplasms, Plasma Cell

NCT01208766 2026-01-06

HO95

Phase 3 Completed

1,503 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Completed

14 enrolled 15 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

Phase 2/3 Not yet recruiting

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT07319897 2026-01-06

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

300 enrolled